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Abstract
Objective: To offer a quantitative risk–benefit analysis of
two doses of SARS-CoV-2 vaccination among adolescents
in England.
Setting: England.
Design: Following the risk–benefit analysis methodology
carried out by the US Centers for Disease Control, we
calculated historical rates of hospital admission, Intensive
Care Unit admission and death for ascertained SARS-CoV-
2 cases in children aged 12–17 in England. We then used
these rates alongside a range of estimates for incidence of
long COVID, vaccine efficacy and vaccine-induced myocar-
ditis, to estimate hospital and Intensive Care Unit admis-
sions, deaths and cases of long COVID over a period of 16
weeks under assumptions of high and low case incidence.
Participants: All 12–17 year olds with a record of con-
firmed SARS-CoV-2 infection in England between 1 July
2020 and 31 March 2021 using national linked electronic
health records, accessed through the British Heart
Foundation Data Science Centre.
Main outcome measures: Hospitalisations, Intensive Care
Unit admissions, deaths and cases of long COVID averted
by vaccinating all 12–17 year olds in England over a 16-
week period under different estimates of future case
incidence.
Results: At high future case incidence of 1000/100,000
population/week over 16 weeks, vaccination could avert
4430 hospital admissions and 36 deaths over 16 weeks.
At the low incidence of 50/100,000/week, vaccination
could avert 70 hospital admissions and two deaths over
16 weeks. The benefit of vaccination in terms of
hospitalisations in adolescents outweighs risks unless case
rates are sustainably very low (below 30/100,000 teen-
agers/week). Benefit of vaccination exists at any case rate
for the outcomes of death and long COVID, since neither
have been associated with vaccination to date.
Conclusions: Given the current (as at 15 September 2021)
high case rates (680/100,000 population/week in 10–19
year olds) in England, our findings support vaccination of
adolescents against SARS-CoV2.
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Introduction
On 19 July 2021, the Joint Committee on Vaccination
and Immunisation, which advises on vaccine policy in
England and Wales, recommended that COVID-19
vaccines should not be offered to all 12–17 year-
olds, judging that any health benefits relative to
potential risks were marginal.1 This decision was
made even though the UK’s Medicines and
Healthcare Products Regulatory Agency, having
sought expert advice from the independent
Commission on Human Medicines, had approved
the use of the Pfizer/BioNTech vaccine for those
Journal of the Royal Society of Medicine; 0(0) 1–12
DOI: 10.1177/01410768211052589
! The Royal Society of Medicine 2021
Article reuse guidelines: sagepub.com/journals-permissions
aged 16 years and above in December 2020, and for
12–15 year-olds on 4 June 2021.2 The Joint
Committee on Vaccination and Immunisation ini-
tially recommended that vaccines should only be
offered to those under 18 who were either living
with immunosuppressed household members or
had one of a specified set of pre-existing conditions,
later updating this position3 by offering a first dose
of vaccine to all 16–17 year olds, with a decision on
second doses delayed pending further assessment by
the Joint Committee on Vaccination and
Immunisation. Subsequently, on 3 September,4 the
Joint Committee on Vaccination and Immunisation
further updated their advice suggesting that risks
and benefits of vaccination were finely balanced,4
stating that the majority of the more severe out-
comes occurred in children with pre-existing condi-
tions, among whom the risk, and therefore the
potential benefit, appeared to be higher.4 However,
their analysis did not assess the risk posed by long
COVID, which can occur in all children, and can
lead to persistence of symptoms in 2–14% of chil-
dren for 4–16 weeks or longer.5–10 Nor did it assess
benefits to children through reduction of educational
disruption, reduced risk to household members or
broader societal benefits through reduction in over-
all transmission due to higher population immun-
ity.4 Based on their assessment, the Joint
Committee on Vaccination and Immunisation did
not recommend routine vaccination of adolescents.4
On 13 September,11 based on the assessment by the
Joint Committee on Vaccination and Immunisation,
and additional consideration of direct benefits to
children from reduced educational disruption, the
four UK Chief Medical Officers recommended a
single dose of vaccine Intensive Care Unit for all
12–15 year olds, pending further assessment.
The Joint Committee on Vaccination and
Immunisation position and UK policy contrasts with
the policies of many other countries, including the US,
Canada, Australia, New Zealand, Israel and much of
Europe and Southeast Asia, that are currently offering
two doses of vaccines to all 12–17 year-olds. The
European Medicines Agency has authorised both the
Pfizer/BioNTech (Comirnaty) and Moderna
(Spikevax) vaccine for 12–17 year olds.12,13 To date,
the US has fully vaccinated 10 million under-18s,
including over six million 12–15 year olds and has
administered at least one dose to over 12 million
under-18s, including almost eight million 12–15 year
olds.14 France has already fully vaccinated 52% of its
12–17 year olds, and the majority of adolescents have
received at least a single dose in Denmark and Spain.15
The USA was one of the first countries to offer
vaccines to adolescents.16 This decision was based
on quantitative analysis of the potential risks and
benefits of vaccination in children conducted by the
US Centers for Disease Control and Prevention,6
considering in particular the risk of myocarditis and
pericarditis.17–20 These have a rare association (30–40
cases/million doses) with COVID-19 vaccination,17,20
particularly following second doses. Thus far, as per
the joint statement issued by the Centers for Disease
Control, the American Academy of Paediatrics, and
several other organisations, almost all cases of vac-
cine attributable myocarditis/pericarditis in young
people have been mild, and have recovered with no
or minimal treatment.18,19,21,22 There have been no
vaccine-related deaths recorded, and no serious
adverse events observed in over 10 million under-
18s vaccinated to date. The UK analysis of Yellow
Cards (notifications of adverse events) by the
Medicines and Healthcare Products Regulatory
Agency, also states that these events have been extre-
mely rare, typically mild and with rapid recovery.23
On the other hand, COVID-19 illness can be asso-
ciated with myocarditis,18,24–27 and hospitalisation
has been associated with long-term neurological
impacts, even in those under 18 years of age.28
Based on their quantitative analysis, the Centers for
Disease Control concluded that the potential benefits
did outweigh the risks16,17 and recommended vaccin-
ation for all children aged 12–15.16 In their analysis,
the Centers for Disease Control used rates of infec-
tion in the US from 21 May 2021, assuming these
would remain constant over the following 120 days
and used a hospitalisation rate of 0.8/100,000 popu-
lation/week.17
Analysis by the UK Joint Committee on
Vaccination and Immunisation
The publicly available versions of the Joint
Committee on Vaccination and Immunisation rec-
ommendations contain limited quantitative analyses
of the benefits and risks to 12–17 year olds.1,3,4 In
their first statement on 19 July, they estimated a
COVID-19 attributable mortality rate of two per
million in England and hospitalisation rate of 100–
400 per million (during the second wave) in the UK
among children and young people (under 18 years of
age). They did not give a denominator, but these
estimates appeared to use the whole population of
under-18s in England (30 deaths in just over 12 mil-
lion children), rather than using the number of
reported COVID-19 cases or an estimate of overall
infections as the denominator. The use of rates
based on the total population substantially under-
estimates the risks of these outcomes in children
infected with SARS-CoV-2, unless it is assumed
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that every child has been infected. This is both
implausible and inconsistent with data on antibody
prevalence.1
The most recent Joint Committee on Vaccination
and Immunisation statement published on
3 September 2021, while providing numbers for risk
of Intensive Care Unit admission to healthy 12–15
year olds, and estimates of hospitalisations and
Intensive Care Unit admissions averted, does not
clarify what hospitalisation rates were assumed,
what the denominator was for Intensive Care Unit
admission rate, how this modelling was carried out
or what future infection exposure was considered
over what period of time.4 Neither does the analysis
consider the impact of long COVID, a clinically sig-
nificant complication of SARS-CoV-2 infection that
occurs in somewhere between 2% and 14% of cases,
even in healthy children.5–10 The longer term conse-
quences of acute COVID-19 infection are also not yet
known, but emerging studies show persistent changes
in multiple organs,27 including the brain,28,29
heart,24–26 lungs and kidneys.27
COVID-19 outcomes depend on risks of exposure,
rather than total population size. Exposure to infec-
tion varies considerably over time and depends on
context such as vaccination coverage and protective
public health measures. The higher exposure is, the
greater the benefit of vaccination (as it averts more
cases for the same number of people vaccinated).
Thus, any risk–benefit analysis must consider
potential benefits of vaccination at different levels
of exposure to infection, as done by the Centers for
Disease Control.
Current context in England
June to August 2021 saw very high case incidence
rates in 12 to 17 year olds (500 to 1000 cases per
100,000 people per week).30 Official mandates for
nearly all mitigations, including mask mandates,
social distancing and self-isolation requirements for
vaccinated adult contacts and children under 18 have
been removed in England. There have been over 3400
hospitalisations in under-18s with COVID-19 since 4
June (when the Pfizer vaccine was approved for 12–15
year olds by the Medicines and Healthcare Products
Regulatory Agency), including over 1700 hospitalisa-
tions among 6–17 year olds,31 with the majority of
these directly attributable to COVID-19 (Public
Health England COVID-19 Health Inequalities
Monitoring for England and International Severe
Acute Respiratory and Emerging Infection
Consortium).32,33 Case rates fell in under-18s after
the end of the summer school of term but have
been increasing again since August.34 Hospital admis-
sions in 6–17 year olds remain at levels near the
winter peak (Figure 1). Government advisors have
warned that significant increases35 in infections are
likely following the recent return to school in
September.
Figure 1. Time series of daily hospital admissions (seven-day running average) with COVID-19 among 6–17 year olds from
1 April 2020 to 13 September 2021.
Data downloaded from https://api.coronavirus.data.gov.uk/v2/data?areaType¼nation&areaCode¼E92000001&metric¼cumAdmiss
ionsByAge&format¼csv.
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Objective
In this paper, we offer a quantitative assessment of
the benefits and risks of vaccination in 12–17-
year-olds for England over a range of case incidence
rates. To be consistent with the Joint Committee on
Vaccination and Immunisation remit, we consider
only direct benefit to children from vaccination and
do not consider secondary benefits such as onward
transmission or educational disruption.
Methods
Using the Centers for Disease Control analysis as a
template,17 we examined the potential benefits and
risks of offering vaccines to England’s 3.9 million
12–17 year olds ahead of school reopening in
September 2021. To do this, we extracted data on
the number of 12–17 year olds in England diagnosed
with COVID-19 and the related hospitalisations and
deaths, during the period from 1 July 2020 to 31
March 2021. This period was chosen to exclude the
first wave of the pandemic when few children were
tested for SARS-CoV-2. Linked data since 31 March
2021 are not yet available. Data were obtained using
linked electronic health records from multiple sources
(accessed through the British Heart Foundation Data
Science Centre).36 We used information from: (a) the
Public Health England Second Generation
Surveillance System national testing laboratory, (b)
primary care consultations in General Practice
Table 1. Data used to estimate hospitalisations, deaths, Intensive Care Unit admissions, vaccine-associated myocarditis and long
COVID.
Numbers Percentage of cases
Total population 12–17 year olds 3,918,373
Boys 2,011,458
Girls 1,906,915
COVID-19 diagnosed cases 1 July 2020–31 March 2021 169,412
Hospitalised 1390 0.820
Intensive Care Unit admissions 91 0.054
Ventilated in Intensive Care Unit or outside Intensive Care Unit setting 75 0.044
Died 11 0.006
Long COVID (12 weeks) (2%,4% and 14% incidence)6–10 6,776 (4%) 2, 4, 14
Vaccine-associated myocarditis/pericarditis
Boys (12–17 year old) (per million)17–20 6.72 (1st dose)
62.75 (2nd dose)
Girls (12–17 year old) (per million)17–20 0 (1st dose) 8.68 (2nd dose)
Note: These data have been extracted through linkage of electronic health records from multiple sources to assess the total number of children
identified with a COVID-19 infection, and related hospitalisations, intensive care admissions, ventilatory support and deaths (data accessed through the
British Heart Foundation Data Science Centre).15 Data sources include Second Generation Surveillance System national testing laboratory, primary
care consultations in General Practice Extraction Service Data for Pandemic Planning and Research using SNOMED-CT terms, Hospitalisations are
identified from an admission in Hospital Episode Statistics Admitted Patient Care or Secondary Uses Service containing COVID-19 ICD-10 diagnosis
or an entry in COVID-19 Hospitalisations in England Surveillance System. Intensive Care Unit admissions are identified by an entry in Hospital Episode
Statistics Critical Care or from. Ventilatory support is identified from the COVID-19 Hospitalisations in England Surveillance System, Hospital Episode
Statistics Critical Care (basic or advanced respiratory support days> 0) and Hospital Episode Statistics Admitted Patient Care and Secondary Uses
Service (OPCS-4 procedure codes for continuous positive airway pressure, non-invasive ventilation, invasive ventilation, intubation of trachea and
extracorporeal membrane oxygenation). Deaths are identified from Office of National Statistics Deaths Registry, with COVID-19 as a named cause of
death or within 28 days of an individual’s first COVID-19 event as well as from Hospital Episode Statistics Admitted Patient Care or Secondary Uses
Service admissions with a discharge method or destination denoting death. Patients were included in the analyses if they resided in England, were alive
on the study start date, registered with a primary care practice, had a valid pseudo-identifier for linkage and at least 28 days of follow-up. We used the
period from 1 July 2020 to 31 March 2021 to exclude the first wave of infections when few children were tested for COVID-19.15
Total number of 12–17yr olds taken from Office for National Statistics population estimates for England: mid-2020 for persons by single year of age.
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Extraction Service Data for Pandemic Planning and
Research, (c) hospitalisations (including Intensive
Care Unit admissions and ventilation care provided
outside of an Intensive Care Unit) from Hospital
Episode Statistics and the COVID-19
Hospitalisations in England Surveillance System
and (d) deaths from Office of National Statistics.
Patients were included in the analyses if they resided
in England, were alive on the start date of the study
period, registered with a primary care practice, had a
valid pseudo-identifier for linkage and at least 28
days of follow-up. Using this individual-level linked
dataset, we calculated the proportion of hospitalisa-
tions, Intensive Care Unit admissions and deaths
associated with identified infection (Table 1).
Using these proportions and varying future
COVID-19 case incidence rates, we estimated the
number of COVID-19-related hospitalisations, inten-
sive care unit admissions and deaths expected over
the 16 weeks from September to December 2021, and
the number of cases of long COVID that would arise,
without vaccination. We defined long COVID
broadly as persistent symptoms following acute infec-
tion for 12 weeks or more. In line with this definition,
we considered three estimates based on recent studies
on long COVID: 2% (Molteni et al.),10 4% (Radke
et al.)7 and 14% from the large-scale CLoCk study.6
We note that these estimates encompass the estimates
recently reported by the Office for National Statistics,
which identified self-reported long COVID preva-
lence of 6%5 among 12–16 year olds. Differences in
estimates likely arise from different symptom lists,
time gaps allowed between symptoms, treatment of
missing data, case ascertainment and time spans for
determining long COVID. Using a broad range of
estimates allows for the uncertainty in the prevalence
of long COVID and allows us to ascertain benefit
across a range of possible scenarios.
We use ascertained case rates (which do not cap-
ture all infections since they rely on a positive test) to
calculate historical rates of adverse outcomes and to
project forward. We chose this approach, as Public
Health England incidence data reported in England
are based on ascertained cases,30 and data on ascer-
tained cases are more robust and can be linked at an
individual level to outcomes. Using the same denom-
inator consistently as we have done would produce
the same estimates of hospitalisations and deaths as
using infection rates, infection fatality and infection
hospitalisation rates. However, this does assume that
the proportion of infections ascertained as cases
through testing remains relatively constant over
time. To assess the impact of violations of this
assumption, we also carried out a sensitivity analysis
using lower hospital admission to case ratios to
generate outcomes, allowing for the possibility that
case ascertainment has improved over time.
Given the projected estimates are based on recent
and current per-population case incidence rates per
week, as reported weekly by Public Health England,
these implicitly account for the proportion of chil-
dren susceptible to SARS-CoV-2, which is not
expected to change markedly over a period of 16
weeks, even in our high incidence scenario, thereby
eliminating the need to explicitly model susceptibility
during the 16-week period.
We used Centers for Disease Control estimates of
vaccine-associated myocarditis/pericarditis following
the first and second doses of vaccine,17–20 assuming
all 12–17 year olds in England were vaccinated. These
are the same estimates that the Joint Committee on
Vaccination and Immunisation refer to in their state-
ment and are compatible with yellow card reporting
from the Medicines and Healthcare Products
Regulatory Agency. Next, we examined how many
COVID-19-related outcomes would be averted by
vaccination of all 12–17 year olds, assuming conser-
vative estimates of vaccine effectiveness in reducing
severe outcomes (90% with the Delta variant among
the fully vaccinated) and infections (64% among the
fully vaccinated),37–39 assuming no additional protec-
tion against long COVID once infected. We calcu-
lated total hospitalisations averted assuming the
worst-case scenario of all cases of vaccine-associated
myocarditis requiring hospital admission.
Given the difficulty in predicting infections over
time, we examined outcomes across a broad range of
average future ascertained case incidence rates over a
fixed period of 16 weeks. Full outcomes are shown for
two levels of exposure: late July 2021 ascertained case
rates in 12–17 year olds of 1000 per 100,000 popula-
tion per week30 for 16 weeks and a 20-fold lower level
of exposure of 50 per 100,000 population per week for
16 weeks, comparable to the end of April 2021. We
note that the high incidence scenario is possible given
the case rates in Scotland reached 1800 per 100,000
population per week in all children under 1540 and
2700 per 100,000 population per week33 in 14 to 15
year olds in early September 2021 following school
opening in mid-August. Approximately 5% of all
under-15s in Scotland have had a new confirmed infec-
tion in the month since school opening.40
We also calculated expected hospital admissions
across the full range of ascertained case rates from
0 to 1000/100,000/week, to find the minimum ascer-
tained case incidence threshold at which benefit tilts
from no vaccination towards vaccination.
In presenting results, we round all estimates higher
than 50 to the nearest 10 or to two significant figures
if more than 1000.
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Results
We estimated that, if the late July 2021 rates of infec-
tion among 12–17 year olds (1000 per 100,000 per
week) continued over 16 weeks in England, this
would lead to 5100 hospitalisations, 340 admissions
to Intensive Care Unit (with 280 adolescents requir-
ing ventilation) and 40 deaths. Vaccination is esti-
mated to avert 4590 COVID-19 hospitalisations,
310 Intensive Care Unit admissions, 250 needing ven-
tilation and 36 deaths, with the disbenefit of 160 cases
of vaccine-associated myocarditis/pericarditis (see
Figure 2(a)). Under the assumption that all 160
cases of vaccine-associated myocarditis/pericarditis
required hospitalisation, vaccination would still
avert 4400 hospitalisations. For long COVID, vaccin-
ation would avert 56,000, 16,000 or 8000 cases in 12–
17 year olds assuming incidence rates of 14%, 4%
and 2%, respectively.
Examining the low-incidence scenario of 50 per
100,000 per week, vaccination could avert 230
hospitalisations, 15 admissions to Intensive Care
Unit, two deaths and 2800/800/400 cases of long
COVID (14%/4%/2% incidence, respectively), at
the same cost of 160 cases of vaccine-associated myo-
carditis/pericarditis (see Figure 2(b)), averting a total
of 70 hospitalisations. The risk of hospitalisation with
vaccination only exceeds the risk of hospitalisation
with COVID-19 when the case incidence is below
30 per 100,000 per week; a level that has not been
seen in adolescents in the UK in 2021 (Figure 3(a)).
Due to the differential risk of vaccine-related myocar-
ditis in boys and girls, this threshold is 50 per 100,000
per week for boys and below 10 per 100,000 per week
for girls (Figure 3(a)). Even at these low incidence
rates, vaccines would still provide protection against
death (Figure 3(b)) and long COVID outcomes
(Figure 2(b)).
We note that our analysis remains robust in the
face of substantial changes in the parameters exam-
ined. For example, even if we assume that case ascer-
tainment has improved among 12–17 year olds in
Figure 2. Risk–benefit of COVID-19 vaccination in adolescents at high and low incidence levels. (a and b) A comparison of
specific outcomes among adolescents aged 12–17 years of age calculated over a 16-week period assuming different levels of
exposure with high incidence of 1000 per 100,000 per week (reflecting the current case rates in this age group in England) and low
incidence of 50 per 100,000 per week, corresponding to end of April 2021. Note: the scales for (a) and (b) are different for ease of
visualisation. In all cases, direct benefits of vaccination appear to considerably outweigh risks. Values above 50 have been rounded
to the closest 10. Myocarditis here refers to both vaccine-related myocarditis and pericarditis. We show long COVID estimates
assuming an incidence rate of 4% – see results section for equivalent estimates of 2% and 14% incidence. *Note: Total hospitalised
considers hospitalisations from COVID-19 and vaccine-related myocarditis/pericarditis (assuming a worst-case scenario that all
cases of myocarditis are hospitalised).
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more recent periods due to increased testing (e.g. with
rapid tests) resulting in lower ascertained case hospi-
talisation rates, a sensitivity analysis assuming a
0.50% hospitalisation rate (instead of 0.82%) suggests
the overall benefit–risk when comparing only hospital-
isations would still be in favour of vaccination down to
an incidence of 60/100,000/week.
Limitations
We have explicitly not factored vaccine uptake into
our analysis because we only considered direct risks
and benefits to children either with or without vac-
cination. Thus, our risk/benefit calculation among
those vaccinated is not changed by considering vac-
cine uptake (as both risks and benefits would change
by an equivalent amount). Were we considering add-
itional secondary impacts on transmission, vaccine
uptake would be a crucial parameter. We note that
considering secondary impacts of vaccination (e.g. on
transmission or educational disruption) would fur-
ther tip the balance towards vaccination.
There will also be some children identified as a
COVID-19 hospital admission where their positive
test is an incidental finding. Addressing these limita-
tions involves challenging analysis that we hope to
undertake in the near future, but the decisions on
vaccinating 12–17 year olds are pertinent now and
we note that neither the Centers for Disease
Control, nor similar European agencies have factored
such considerations into their analysis and advice.
We also note that our analyses would be robust to
substantial changes in hospitalisation rates, as we
have shown in our sensitivity analyses. Finally,
recent reports from SAGE suggest that 80% of hos-
pital admissions in children with COVID-19 were due
to COVID-19.33
It is likely that there is some difference in risk of
hospitalisation in children with and without other
health conditions. Unlike the Joint Committee on
Figure 3. Hospitalisations* and deaths averted by COVID-19 vaccination in adolescents at different incidence levels. (a and b)
The number of hospitalisations,* and deaths averted as a function of case incidence among 12–17 year olds over a 16-week period.
For hospitalisations, we represent these separately for boys and girls to account for the differing rate of vaccine-related
myocarditis. Myocarditis here refers to both vaccine related myocarditis and pericarditis. *Note: Total hospitalised considers
hospitalisations from COVID-19 and vaccine-related myocarditis/pericarditis (assuming a worst-case scenario that all cases of
myocarditis are hospitalised).
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Vaccination and Immunisation, we have not con-
sidered sub-analysis by whether children had pre-
existing conditions, due to lack of available data.
However, while risk of hospitalisation may be much
lower in children without other health conditions, we
note that the majority of hospital admissions with
COVID-19 and Paediatric Intensive Care Unit
admissions with Paediatric Multisystem
Inflammatory Syndrome in children have occurred
in children without pre-existing conditions.41–43
Moreover, the risk of long COVID is likely to be
similar in healthy children (given the estimates from
the Office for National Statistics),5 and our current
analysis of benefits with respect to reduction in long
COVID risk would apply to this group. Therefore,
alongside analyses by the Joint Committee on
Vaccination and Immunisation that show benefit in
reduction of Intensive Care Unit admissions, hospi-
talisation and Paediatric Multisystem Inflammatory
Syndrome,4 our analyses would strongly favour bene-
fits of vaccination when long COVID outcomes are
also considered in this group.
We do not assess Paediatric Multisystem
Inflammatory Syndrome separately in our study. We
expect that, given the majority of cases are admitted to
Paediatric Intensive Care Unit, these would have been
captured in our estimates for Intensive Care Unit
admission. However, we may have underestimated
cases of Paediatric Multisystem Inflammatory
Syndrome in our modelling. This would lead to
more conservative results, thereby underestimating
the benefits of vaccines relative to risks.
Given the uncertainty in long COVID incidence
among adolescents, we have based our assessment
of risk and benefit on a range of estimates based on
recent studies of long COVID.5–10 We note that even
with the most conservative estimates (2% at 12
weeks), there are considerable benefits in prevention
of long COVID from vaccination, particularly given
current incidence rates in England. Notably, the
benefits of vaccination remain clear for ascertained
case incidence rates of over 30/100,000/week even
without factoring in long COVID.
We do not assess risks separately for one dose and
two doses of vaccines, given the considerable uncer-
tainty around the durability, and level of protection
offered by a single dose of vaccine among adoles-
cents. We note that there have been no clinical
trials in adults or adolescents with a single dose of
Pfizer. Our analysis shows that benefits of two doses
of vaccines, which are likely to be needed to provide
maximally effective and durable protection from
infection with the Delta variant of SARS-CoV-2,
far outweigh risk from vaccine-associated
myocarditis.
In reality, case rates will not be constant over 16
weeks and so our calculations should not be taken as
predictions in any sense. However, our analysis
shows that unless there is good reason to believe
that average ascertained case rates will be below 30/
100,000/week for the entire period, then vaccination
will bring a benefit. Thus, our analysis provides a
realistic benchmark to assess vaccine policy. We
also note that the time frame of 16 weeks is somewhat
artificial and children will likely continue to be
exposed to COVID-19 well into 2022, which would
lead to further benefit from vaccination.
Finally, we have not considered the broader logis-
tical factors involved in vaccination of adolescents in
our risk–benefit analysis. This would require further
consideration, with analysis of capacity and resource
requirements to expand the current programme to
these groups.
Discussion
Direct benefit to children
Our analysis shows that vaccination of 12–17 year
olds provides overall benefit in terms of hospital
admissions for average ascertained case rates of
over 30 per 100,000 children aged 12 to 17 per
week. When considering additional outcomes such
as deaths and long COVID, vaccination is always
beneficial, as neither adverse outcome has been
linked to vaccination. Since ascertained case rates in
12–17 year olds have not been as low as 30/100,000/
week in 202130 in England and given likely rates of at
least 20 times higher this next school term (current
rates in England are 680/100,000/week in teen-
agers),30 we conclude that on clinical risks alone, vac-
cination is warranted for 12–17 year olds in England.
SARS-CoV-2 is a neurotropic and pro-inflammatory
virus with neuro-invasive potential; structural
changes in brain tissue have been observed in
adults, including those with mild infection.29 Long
COVID can be associated with multisystem disease
in some children, including myocarditis24–26 and per-
sistent cognitive symptoms. Myocarditis has been
shown to be 37 times more common in under-16s
with COVID-19 compared with those without infec-
tion.24 While we wait to understand the long-term
effects of SARS-CoV-2 upon children, the precau-
tionary principle advocates for protecting all children
from exposure to this virus, and vaccination is a cru-
cial part of that protection where use is authorised.
Additionally, previous data from England also show
that while children with pre-existing illnesses may be
at greater individual risk, 60% of hospitalisations in
under-18s in England have been among children who
8 Journal of the Royal Society of Medicine 0(0)
do not have such conditions,44 suggesting consider-
able benefits for all children in reducing severe illness
through vaccination.
We note that the assumptions and estimates used
in our analysis are conservative. The rates of the out-
comes of interest are based on data prior to 31 March
2021 – before the potentially more severe45 Delta
variant became dominant. Estimates from Public
Health England and Public Health Scotland suggest
that the rate of hospitalisation with Delta is likely to
be 1.5–2 greater than that with the Alpha variant,
although whether this increased severity is seen for
children is not clear.46 Current data from the USA
suggest that indicators of severe disease among hos-
pitalised children during an early period when the
Delta variant predominated were generally similar
to those observed earlier in the pandemic.47 A much
higher number of hospitalisations may been observed
potentially due to greatly increased case numbers as a
result of the markedly increased transmissibility of
the Delta variant. We have used estimates of vaccine
effectiveness that are more conservative than those
published by PHE.48 Consistent with our analyses,
hospitalisations among unvaccinated adolescents
have been 10 times higher than those among vacci-
nated adolescents in the USA.47 In line with the
Centers for Disease Control approach, we have con-
sidered the risks and benefits over a limited time
period. Using less conservative estimates of efficacy
or projecting over longer time periods will further
favour vaccination.
Although our analysis is based on data from
England, the same calculations can be made for
other countries, using appropriate country-specific
data. To assist this process, we have made our cal-
culations spreadsheet publicly available (see supple-
mental data) for scrutiny and for widespread use. We
welcome such scrutiny and invite the Joint
Committee on Vaccination and Immunisation to
examine our analysis. We also invite the Joint
Committee on Vaccination and Immunisation to
similarly make available the data and calculations
on which they have based their own conclusions.
Wider benefits of vaccination
As discussed, we have only considered the direct
impacts of vaccination on health outcomes in 12–17
year olds, to be consistent with the approach taken by
the Joint Committee on Vaccination and
Immunisation. The Joint Committee on Vaccination
and Immunisation have not formally evaluated the
impact of vaccination upon community transmis-
sion.1 However, given that Joint Committee on
Vaccination and Immunisation has recommended
vaccination for 12–17 year olds living with immuno-
compromised family members, there is clearly a case
for considering the additional benefits in terms of
reduced community transmission. Children are a
part of the wider community, and vaccinating them
is likely to have benefits beyond prevention of child-
hood illness. Almost 9000 children in England and
Wales have lost at least one primary carer to
COVID-19 during the pandemic.51 The impact of
bereavement at an early age cannot be overstated.
Vaccinating children will reduce onward transmission
to household members, and protect them as well from
illness, long COVID and severe outcomes from
COVID-19.
Models examining vaccine roll-out in younger age
groups or groups with high levels of contact49 suggest
that vaccination could have substantial impacts upon
reducing community transmission, thereby providing
much greater protection at population level. Indeed,
modelling suggests that vaccinating only a part of the
population, while transmission is allowed to continue
at high levels, creates conditions permissive for viral
adaptation towards potential immune escape.49,50
Vaccinating adolescents would also protect children
and siblings who are not eligible for vaccination, and
education staff who interact directly with children in
schools. Recent data suggest that 2.3% and 1.95% of
all education and teaching staff had long COVID
symptoms lasting four weeks and 12 weeks or more,
respectively, on 1 August 2021, the third highest across
all occupations examined.52 Reduction in transmission
in schools is likely to have broader protective effects,
reducing risk to education staff engaged in face-to-face
interactions. While the vast majority of education staff
are likely to be double vaccinated, the protection from
infection is partial, and reduction in exposure would
provide further protection.
Another major consideration is the benefit of
vaccination in terms of reducing education disruption
for children, given that children testing positive
must isolate at home for 10 days and potential
impact on education for children who experience
symptoms for longer than 10 days. Even mild initial
symptoms or long COVID symptoms that resolve
fully after several months could have a significant
impact upon children if illness falls during exam per-
iods. Factoring in these various indirect benefits
would tilt the balance further in favour of
vaccination.
Additional protections alongside vaccination
Immunisations take time, and even with this protec-
tion, outcomes are better when risk of exposure is
lower. England has failed to put in place adequately
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robust preventative measures in schools thus far,53
and has removed ones that were in place going for-
ward (no mask mandates, minimal contact tracing
within schools, no requirement for under-18s to iso-
late if a household member tests positive). Since com-
munity transmission rates remain high and most
adolescents were not eligible for vaccination before
the start of the new academic year, it is vital that
the UK Government invests in mitigations for
schools,53 including assessment and provision of ade-
quate supplemental ventilation. As the Centers for
Disease Control has recently emphasised, controlling
spread of the Delta variant requires maximum pre-
ventive measures including vaccination, masking and
ventilation.54,55 It is not an either-or; a comprehen-
sive ‘vaccines plus’ approach is needed.
Conclusions
In summary, our conservative analysis shows that the
benefits of offering two doses of vaccine to all 12–17
year olds clearly outweigh the risks to the children
concerned in both the current context and in scen-
arios with substantially lower case incidence rates.
The real-world short-term risks from vaccination in
over 12 million under-18s who have been vaccinated
around the world have been found to be minimal,
with myocarditis being a rare and typically mild com-
plication. The known impact of COVID-19 on ado-
lescents is concerning, and it is clear that vaccines can
avert much of this impact even at current case inci-
dence rates in England.
Supplemental data
A supplemental spreadsheet providing the calcula-
tions used in this paper is available online. This can
be used to calculate parameters for other settings and
other times.
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